Childhood Dementia: Parents Share Heartbreaking Decision to Terminate Pregnancy

A mother from London has shared her deeply personal story of learning that her toddler has a rare form of childhood dementia, and that prenatal testing revealed her unborn child also carried the same genetic condition, leading to the heartbreaking decision to terminate the pregnancy.

The woman, identified only by her first name Jennifer in media reports, described the initial diagnosis of her two-year-old daughter as “the worst moment of my life.” The child was diagnosed with a neurodegenerative disorder linked to a genetic mutation, specifically a form of neuronal ceroid lipofuscinosis (NCL), commonly referred to as Batten disease, which falls under the broader category of childhood dementias.

Childhood dementia is not a single disease but an umbrella term for over 70 rare genetic disorders that cause progressive cognitive decline in children. These conditions, which include various forms of NCL, Rett syndrome, and Sanfilippo syndrome, lead to the loss of previously acquired skills such as speech, mobility, and memory, often resulting in severe disability and early death.

According to the Child Dementia Initiative, a global advocacy group, approximately 700,000 people worldwide live with childhood dementia, with a new case diagnosed every seven minutes. Despite its prevalence being comparable to cystic fibrosis in some regions, childhood dementia remains significantly under-recognized and underfunded in research and public health policy.

In Jennifer’s case, genetic testing confirmed that both her toddler and the fetus she was carrying shared the same pathogenic mutation. Upon receiving the prenatal results, she and her partner made the difficult decision to end the pregnancy, stating they felt they had “no choice” given the prognosis and the emotional and caregiving toll already experienced with their first child.

“We loved our unborn child, but we could not subject another baby to the same inevitable decline,” Jennifer said in an interview with the Daily Mail. “Watching our daughter lose the ability to walk, talk, and recognize us has been devastating. We knew what was coming for the second child, and we could not go through that again.”

The decision to terminate a pregnancy based on a fatal or severely disabling genetic diagnosis is legally permitted in the United Kingdom under the Abortion Act 1967, which allows terminations when there is a substantial risk that the child would be born with a serious physical or mental abnormality. In such cases, there is no upper gestational limit for termination.

Medical professionals emphasize that prenatal genetic screening and diagnostic testing, such as amniocentesis or chorionic villus sampling (CVS), can detect certain inherited conditions early in pregnancy. These tests are typically offered when there is a known family history of a genetic disorder or when screening results indicate increased risk.

Experts in neurogenetics note that while advances in genetic testing have improved diagnostic accuracy, they also present families with profound ethical and emotional challenges. Genetic counselors play a key role in helping parents understand test results, inheritance patterns, and available options, including prenatal diagnosis, preimplantation genetic testing (PGD), and preparation for raising a child with a life-limiting condition.

Dr. Sara Mole, a professor of cell biology at University College London and a leading researcher in Batten disease, explained that while there is currently no cure for most forms of childhood dementia, emerging therapies such as enzyme replacement therapy, gene therapy, and antisense oligonucleotides are under investigation. Some treatments have shown promise in slowing disease progression in clinical trials, particularly for specific subtypes like CLN2 disease.

For example, cerliponase alfa (Brineura®), an enzyme replacement therapy, was approved by the European Medicines Agency in 2017 for the treatment of CLN2 disease, a specific form of NCL. It has been shown to slow the loss of walking ability in symptomatic pediatric patients. However, it does not address cognitive decline, and access to such treatments remains limited and costly.

Jennifer said she hopes sharing her story will raise awareness about childhood dementia and the need for better support systems for families facing similar diagnoses. “We need more research, better access to genetic counseling, and compassionate care pathways,” she said. “No parent should have to make this kind of decision alone.”

Support organizations such as the Batten Disease Family Association (BDFA) in the UK and the Child Dementia Initiative provide resources, advocacy, and community connections for affected families. They continue to call for increased funding for research into disease-modifying treatments and improved neonatal and prenatal screening protocols.

As genetic testing becomes more routine in prenatal care, stories like Jennifer’s highlight the complex intersection of medical advancement, personal autonomy, and ethical decision-making. While science can now predict certain devastating outcomes with greater accuracy, society continues to grapple with how best to support families navigating these realities.